Sonoma Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

9. Significant Customer Concentrations

9. Significant Customer Concentrations	6 Months Ended
Sep. 30, 2013
Risks and Uncertainties [Abstract]
9. Significant Customer Concentrations	For the three months ended September 30, 2013, one customer represented 33% of net revenue and one customer represented 32% of net revenue. For the three months ended September 30, 2012, one customer represented 27% of net revenue. For the six months ended September 30, 2013, one customer represented 37% of net revenue and one customer represented 27% of net revenue. For the six months ended September 30, 2012, one customer represented 28% of net revenue. At September 30, 2013, one customer represented 33%, one customer represented 30%, and one customer represented 11% of the net accounts receivable balance. At March 31, 2013, one customer represented 34%, one customer represented 26%, and one customer represented 15% of the net accounts receivable balance.

9. Significant Customer Concentrations

6 Months Ended

Sep. 30, 2013

For the three months ended September 30, 2013, one customer represented 33% of net revenue and one customer represented 32% of net revenue. For the three months ended September 30, 2012, one customer represented 27% of net revenue.

For the six months ended September 30, 2013, one customer represented 37% of net revenue and one customer represented 27% of net revenue. For the six months ended September 30, 2012, one customer represented 28% of net revenue.

At September 30, 2013, one customer represented 33%, one customer represented 30%, and one customer represented 11% of the net accounts receivable balance. At March 31, 2013, one customer represented 34%, one customer represented 26%, and one customer represented 15% of the net accounts receivable balance.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References + Details